The pharmacokinetics and pharmacodynamics of repeated oral administration of furosemide were studied in patients with chronic renal failure or nephrotic syndrome using three different dosage regimens (4 x 40, 4 x 80 and 4 x 250 mg/d). Concentrations of the unchanged drug in serum and urine were measured fluorometrically. The elimination kinetics of furosemide was linear over the dose range studied. In contrast, the bioavailability of this diuretic decreased with increasing doses. The diuretic effects of all three dosage regimens were distinct only on the first day of therapy, thereafter decreasing rapidly. It can be concluded that the hormonal regulation of water and electrolyte balance are responsible for this behavior rather than pharmacokinetics. Creatinine and urea nitrogen excretion were not influenced by any furosemide dosage regimen.
Download full-text PDF |
Source |
---|
Front Biosci (Landmark Ed)
January 2025
Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China.
Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use.
View Article and Find Full Text PDFPharmaceutics
January 2025
Université de Lorraine, F-54000 Nancy, France.
Curcumin, a bioactive compound derived from the rhizome of L., has garnered significant attention for its potent anticancer properties. Despite its promising therapeutic potential, its poor bioavailability, rapid metabolism, and low water solubility hinder curcumin's clinical application.
View Article and Find Full Text PDFPharmaceutics
January 2025
Division of Clinical Pharmacology, Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD 21287, USA.
Long-acting and extended-release drug delivery strategies have greatly improved treatment for a variety of medical conditions. Special populations, specifically infants, children, young people, and pregnant and postpartum women, could greatly benefit from access to these strategies but are often excluded from clinical trials. We conducted a systematic review of all clinical studies involving the use of a long-acting intramuscular injection or implant in infants, children, young people, and pregnant and postpartum people.
View Article and Find Full Text PDFPharmaceutics
January 2025
Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
This in vivo study introduces a newly developed spirooxindole derivative that is deemed safe and effective as a potential targeted therapy for various cancers. Extensive in vivo investigations, including histopathology, immunohistochemistry, and molecular biology, validated its potential for further preclinical and clinical exploration, necessitating comprehensive examinations of its bioavailability, pharmacodynamics, and pharmacokinetics. Additionally, this study involves the development of a commercially viable proniosomal drug delivery system for the compound, facilitating controlled drug release.
View Article and Find Full Text PDFPharmaceutics
January 2025
Department of Pharmaceutical Bioscience, Translational Drug Discovery and Development, Uppsala University, SE-75124 Uppsala, Sweden.
: N-acetyl-galactosamine small interfering RNAs (GalNAc-siRNA) are an emerging class of drugs due to their durable knockdown of disease-related proteins. Direct conjugation of GalNAc onto the siRNA enables targeted uptake into hepatocytes via GalNAc recognition of the Asialoglycoprotein Receptor (ASGPR). With a transient plasma exposure combined with a prolonged liver half-life, GalNAc-siRNA exhibits distinct disposition characteristics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!